NCT01423851View on ClinicalTrials.gov

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 22, 2020

Study Completion Date

April 22, 2020

Conditions
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Interventions
DRUG

NS-018

Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).

Trial Locations (9)

10021

Weill Cornell Medical College, New York

32224

Mayo Clinic, Jacksonville, Jacksonville

48109

University of Michigan, Ann Arbor

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

77030

MD Anderson Cancer Center, Department of Leukemia, Houston

85259-5499

Mayo Clinic Scottsdale Recruiting, Scottsdale

92093-0698

UC San Diego Moores Cancer Center, San Diego

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

NS Pharma, Inc.
All Listed Sponsors
lead

NS Pharma, Inc.

INDUSTRY

NCT01423851 - Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | Biotech Hunter | Biotech Hunter